Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening
World Journal of Urology · 2024
DOI: 10.1007/s00345-024-04905-6 ↗Kurz gefasst
Leserbrief in der Zeitschrift World Journal of Urology, 2024. Verfasst von Takeshi Takahashi. Beteiligte Einrichtung: Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, 803-8501, Japan. jazzy@kuhp.kyoto-u.ac.jp. Hauptthemen laut MEDLINE: Early Detection of Cancer, Prostatic Neoplasms. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health and Welfare Bureau, Kitakyushu City Office, Jyonai 1-1, Kitakyushu, 803-8501, Japan. jazzy@kuhp.kyoto-u.ac.jp.
Zitieren
APA
Takahashi, T. (2024). Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening. World Journal of Urology. https://doi.org/10.1007/s00345-024-04905-6
Vancouver
Takahashi T. Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening. World Journal of Urology. 2024. doi:10.1007/s00345-024-04905-6
BibTeX
@article{Takahashi2024,
author = {Takahashi, Takeshi},
title = {Evidence for clinically significant prostate cancer, overdiagnosis, active surveillance, and PSA screening},
journal = {World Journal of Urology},
year = {2024},
doi = {10.1007/s00345-024-04905-6}
}
EUVIMED